Heron Therapeutics (HRTX)
(Real Time Quote from BATS)
$1.82 USD
+0.07 (4.00%)
Updated Aug 5, 2025 03:54 PM ET
After-Market: $1.80 -0.02 (-1.10%) 4:10 PM ET
3-Hold of 5 3
C Value F Growth C Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
HRTX 1.82 +0.07(4.00%)
Will HRTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HRTX
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
HRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics
Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates
MTD Q1 Earnings Top Estimates, Sales Decline Y/Y, Shares Rise
Other News for HRTX
Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025 | ...
Heron Therapeutics: Middling Performance From Approved Therapies With No Pipeline
JW Asset Management, LLC Adjusts Position in Establishment Labs Holdings Inc
Heron Therapeutics Holds Annual Stockholders Meeting
Edison, Apple, Oklo, Heron, Fifth Third: Trending by Analysts